Breaking News
March 26, 2019 - Finding the elusive drinking ‘brake’
March 26, 2019 - Using the Mastermind strategy in brain research
March 26, 2019 - Synthetic biological logic gate could one day be used to modify cellular function
March 26, 2019 - Researchers uncover large-scale brain patterns and networks which control sleep
March 26, 2019 - Scientific Symposium at LABVOLUTION focuses on key issues in life sciences
March 26, 2019 - Screen time plus snacking could increase risk for metabolic syndrome in teens
March 26, 2019 - Attention, Seniors: Drink More Water and Head Off Disease
March 26, 2019 - Peptide shows promise for protecting kidneys from nephritis
March 26, 2019 - Causes of diabetes decline or disappear when ‘zombie cells’ are removed, shows study
March 26, 2019 - Scientists identify common genetic variants associated with post-stroke recovery
March 26, 2019 - Study finds link between menopause and changes in body composition
March 26, 2019 - Higher levels of sex hormones in older men related to lower biological age
March 26, 2019 - Research links participation in team sports to larger hippocampal volumes in children
March 26, 2019 - Cerveau announces research collaboration agreement with Eisai for novel tau imaging agent
March 26, 2019 - New technique measures frequency of sounds emitted from biological structures
March 26, 2019 - Removal of ‘zombie cells’ alleviates causes of diabetes in obese mice
March 26, 2019 - Women exposed to deepwater horizon oil spill continue to experience PTSD symptoms
March 26, 2019 - Shaping new treatments for tuberculosis
March 26, 2019 - Understanding genetic interactions holds key to new personalized therapies
March 26, 2019 - Nervous system relies on guidance cues for neuronal axons to reach destinations
March 26, 2019 - Altering gut microbiome may be potential treatment option for PCOS
March 26, 2019 - Moleculin Files with FDA for Expedited Approval Pathway for Annamycin
March 26, 2019 - GPs play pivotal role in ensuring success of new Faster Diagnosis Standard for Cancer
March 26, 2019 - New clues discovered to lung transplant rejection
March 26, 2019 - New study offers insight into development of delusions
March 26, 2019 - Children’s ball pits full of pathogenic microbes
March 26, 2019 - Exploring pathophysiological factors that link sleep problems and Alzheimer’s disease
March 26, 2019 - Walking downhill after meals can reduce bone resorption in postmenopausal women with diabetes
March 26, 2019 - USA LESS Issues Voluntary Nationwide Recall of LEOPARD Miracle Honey Due to Presence of Undeclared Sildenafil
March 26, 2019 - CT scan prior to spine fusion finds almost half of patients had undiagnosed osteoporosis
March 26, 2019 - After 2 Apparent Student Suicides, Parkland Grieves Again
March 25, 2019 - Inherited form of rickets improves more with new injectable medicine than conventional therapy
March 25, 2019 - Trastuzumab Tied to Higher Long-Term Risk for Heart Failure
March 25, 2019 - Personal context directly affects CPAP use
March 25, 2019 - Mosquito tracking key to preventing disease outbreaks
March 25, 2019 - Scientists Detect Hidden Signals from Beneficial Bacteria
March 25, 2019 - Treating women with thyroid antibodies with Levothyroxine do not increase live birth rate
March 25, 2019 - Brain area that only processes spoken, not written words identified
March 25, 2019 - Race and ethnicity influence fracture risk in diabetic patients
March 25, 2019 - Researchers report new regenerative medicine approach for treating osteoarthritis of the knee
March 25, 2019 - Exposure to dim light at night may contribute to spread of breast cancer to bones
March 25, 2019 - Benefits of osteoporosis treatment in postmenopausal women outweigh the perceived risks
March 25, 2019 - Researchers find evidence of Cryptosporidium parasite in Minnesota’s public water systems
March 25, 2019 - Three Clues to Raised Risk of Miscarriage
March 25, 2019 - Structured play helps toddlers self-regulate, altering their life course
March 25, 2019 - Translating horror into justice: Stanford psychiatrist advocates for human rights
March 25, 2019 - HORIBA Medical introduces D-Dimer reagent for Yumizen G hemostasis range
March 25, 2019 - Recurrent pregnancy loss may be caused by sperm DNA damage, finds study
March 25, 2019 - Special Collection tracks development of new diagnostic tests for tuberculosis
March 25, 2019 - Air Force develops genetic test to predict mental performance
March 25, 2019 - To abort or not to abort—making difficult choices alone
March 25, 2019 - Computer vision technology could aid ICU care by spotting movement
March 25, 2019 - IONTAS wins ‘Small Business of the Year’ category at Cambridge News Business Excellence Awards 2019
March 25, 2019 - First postpartum depression drug gets FDA nod
March 25, 2019 - Research Recognition Award will help improve lives of young people with absence epilepsy
March 25, 2019 - Bisphosphonates to treat osteoporosis appears to be beneficial for all women
March 25, 2019 - Time-restricted eating may prove to be a dietary intervention against breast cancer
March 25, 2019 - Researchers develop new augmented reality app to assess spatial memory
March 25, 2019 - Dolomite Bio releases new Drop-seq datasets for single-cell RNA sequencing
March 25, 2019 - Hemoglobin A1c blood test may underestimate prevalence of diabetes
March 25, 2019 - Immune system errors linked to development of childhood leukemia
March 25, 2019 - Eating leafy green vegetables may help maintain muscle strength and mobility
March 25, 2019 - BMA secures state-backed clinical negligence indemnity scheme for GP trainees
March 25, 2019 - Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
March 25, 2019 - Adding breakfast to classrooms may have a health downside
March 25, 2019 - She Was Dancing On The Roof And Talking Gibberish. A Special Kind Of ER Helped Her.
March 25, 2019 - KNAUER introduces new Sepapure FPLC columns and media for protein purification tasks
March 25, 2019 - Weight loss in obese migraine sufferers can improve their quality of life
March 25, 2019 - Exposure to particulate air pollution may lead to reduced sperm production
March 25, 2019 - Synthetic peptide appears to disrupt inflammation and protect kidneys from nephritis
March 25, 2019 - New guideline focuses on strategies to improve health of older adults with diabetes
March 25, 2019 - Study evaluates prescribing of preventive drugs at the end of life in older adults with cancer
March 25, 2019 - Radial or femoral approaches for PCI are equal in terms of survival in heart attack patients
March 25, 2019 - Study shows how some autoimmune diseases are more closely related than others
March 25, 2019 - Long term opioid medications impacts production of important hormones
March 25, 2019 - FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
March 25, 2019 - CDC researchers report on trends in hospital breastfeeding policies
March 25, 2019 - States Push For Caregiver Tax Credits
March 25, 2019 - Females on ketogenic diet fail to show metabolic benefits in animal model
March 25, 2019 - Modulating stiffness of blood-forming stem cells could facilitate mobilization procedures
Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis

Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis

image_pdfDownload PDFimage_print

WEDNESDAY, Feb. 14, 2018 — The “overmedication” of agitated dementia patients — with the use of powerful antipsychotic drugs — is an ongoing issue in U.S. health care.

Now, British researchers say they may have found a medicine that helps ease those symptoms, but in a much safer way.

The newer antipsychotic pimavanserin appears to ease psychosis symptoms in people with Alzheimer’s disease without the serious side effects caused by current antipsychotics, according to a study funded by the drug’s maker.

According to the researchers, psychosis affects up to half of the 45 million Alzheimer’s patients worldwide, and that percentage is even higher among patients with other types of dementia.

Currently, there is no approved safe and effective treatment for this common symptom. Standard antipsychotics are widely used, but they can also raise the risk of falls, stroke and even death, and have been linked to a doubling in the rate of brain function decline, according to the study authors.

One study released earlier this month found that, given these concerns, the percentage of long-term U.S. nursing home residents receiving antipsychotic drugs fell from about 24 percent in late 2011 to less than 16 percent in 2017. But advocates for patients say the rate should still be much lower.

“Psychosis is a particularly terrifying symptom of Alzheimer’s disease,” explained Clive Ballard, the lead author of the current study.

“People may experience paranoia, or see, hear or smell things that are not there. It’s distressing both for those experiencing the delusions and for their [caregivers],” said Ballard, who is professor of age-related diseases at the University of Exeter in England.

The new phase 2 clinical trial included 180 Alzheimer’s patients with psychosis. Ninety of them took pimavanserin and 90 were given a placebo, over a three-month period. The study was funded by Acadia Pharmaceuticals, which markets pimavanserin under the brand name Nuplazid.

Reported Feb. 12 in Lancet Neurology, the study found that pimavanserin seems to alleviate psychotic symptoms without many of the side effects seen with standard antipsychotics.

“It’s particularly encouraging that most benefit was seen in those with the most severe psychotic symptom, as this group is most likely to be prescribed antipsychotics,” Ballard said in a university news release.

“We are talking about vulnerable elderly, frail people who are suffering terrifying symptoms, being sedated with current antipsychotics even though it’s well-known that they cause terrible health issues and even death in people with dementia, and have very little benefit,” he said.

A prior study found that pimavanserin was effective for people with dementia related to Parkinson’s disease, and it’s been approved by the U.S. Food and Drug Administration for this use.

As the researchers explained, the drug works differently from standard antipsychotics, because it blocks a specific nerve receptor (THT2A) in the brain.

One geriatrician who’s unconnected to the study said pimavanserin does show promise.

The new study “demonstrated that the medication was well-tolerated and did reduce hallucinations at week 6,” said Dr. Gisele Wolf-Klein. She directs geriatric education at Northwell Health in Great Neck, N.Y.

Wolf-Klein noted that patients included those “with possible and probable Alzheimer’s disease and psychotic symptoms, including visual or auditory hallucinations, delusions or both.”

She said that the longer-term effectiveness of pimavanserin remains to be seen, but the drug may be useful for patients experiencing “short term delusions, as seen in acute delirium.

“This option is of particular interest since the safety profile of this drug shows no detrimental effect on cognitive and motor symptoms, contrary to atypical antipsychotics,” Wolf-Klein said.

Dr. Gayatri Devi is a neurologist at Lenox Hill Hospital in New York City who often works with Alzheimer’s patients. She stressed that any drug “that is effective for treating psychotic symptoms, which are often more disturbing to caregivers than memory impairment, is very important in allowing patients to function and live at home.”

Indeed, Devi added that “one of the most common reasons for institutionalization is psychotic symptoms, including delusions and hallucinations. Many currently available drugs have serious adverse effects and drugs with fewer side effects are desperately needed.”

According to Ballard’s team, the safety and effectiveness of pimavanserin in reducing psychotic symptoms in dementia is now being assessed in a larger clinical trial in the United States.

More information

The U.S. National Institute on Aging has more about Alzheimer’s disease.

© 2018 HealthDay. All rights reserved.

Posted: February 2018

Tagged with:

About author

Related Articles